01:35 PM EDT, 05/15/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We cut our 12-month target to $216 from $285, 8.2x our 2025 EPS view, a discount to UNH's historical forward average due to regulatory uncertainty. A WSJ article today alleges that the health care fraud unit of the Department of Justice's (DOJ) criminal division is investigating UNH for possible criminal fraud in its Medicare Advantage business. We note this follows a report by the WSJ on February 21 about DOJ launching a civil investigation into UNH's Medicare billing practices, which contributed to our lowered position to Sell from Hold. We think this case will provide a continued overhang on the stock until resolved, which could take anywhere from months to years. We also note as the federal government looks to cut spending, fraud and abuse in Medicare is an easy target that is less politically sensitive than, for example, the Medicaid cuts being debated. Shares are down another 14% today due to the WSJ news report, after falling 18% on Tuesday as UNH pulled guidance and abruptly replaced its CEO.